Januvia is the brand name for sitagliptin, a medication prescribed to improve blood sugar regulation in adults with type 2 diabetes. Produced by Merck and Co., Januvia is intended to be used along with diet and exercise. Evidence on whether Januvia is beneficial for weight loss is conflicting, but the medication does have some effects that might lead to weight loss 2.
Januvia helps to regulate blood sugar by increasing the amount of two hormones that the body produces in response to food intake. This increase in hormones has several effects, and two effects may help with weight loss 2. The hormones decrease the transit time for food to move from the stomach into the intestines, slowing the absorption of glucose into the bloodstream, explains NetDoctor. They also cause a feeling of fullness that helps the person to eat less.
- Januvia helps to regulate blood sugar by increasing the amount of two hormones that the body produces in response to food intake.
- The hormones decrease the transit time for food to move from the stomach into the intestines, slowing the absorption of glucose into the bloodstream, explains NetDoctor.
Janumet & Weight Loss
In pre-approval research evaluating the effectiveness of Januvia for treating type 2 diabetes, the medication generally did not cause weight gain or weight loss, reports eMedTV 2. In addition, people taking Januvia along with metformin for treating type 2 diabetes did not lose more weight than those taking only metformin 2.
In 2008, Merck and Co. presented an analysis of research on Januvia at the American Diabetes Association 68th Annual Scientific Sessions, as reported by "Medical News Today." In comparison with the type 2 diabetes medication glipizide, Januvia was much better at preventing hypoglycemia, or low blood sugar, in type 2 diabetes patients needing medicine to control blood sugar. In addition, participants taking Januvia experienced significant weight loss, although the actual amounts were small on average 2.
Acarbose for Weight Loss
Some people experience side effects when taking Januvia that could cause weight loss 2. These effects include:
- excess gas
- lack of appetite
- abdominal pain
- as listed by NetDoctor
Januvia is not connected with weight gain, according to eMedTV 2. This is an important aspect because many other type 2 diabetes medications cause weight gain. Gaining weight is particularly problematic for type 2 diabetes patients, as many already are overweight, and being overweight can worsen the disorder. In the research analysis by Merck and Co., as detailed by "Medical News Today," patients taking glipizide experienced a small but significant weight gain.
- Januvia is not connected with weight gain, according to eMedTV 2.
- In the research analysis by Merck and Co., as detailed by "Medical News Today," patients taking glipizide experienced a small but significant weight gain.
Janumet & Weight Loss
Acarbose for Weight Loss
Betahistine Hydrochloride & Weight Loss
Depression Medications That Will Make You Lose Weight
Alternatives for Januvia
Does Remeron Slow Your Metabolism Down?
Anti-anxiety Medications That Cause Weight Loss
Boswellia Serrata Extract Interactions
Weight Loss or Gain With Celexa
Information on Metformin HCl ER 500 MG for Weight Loss
- Fierce Biotech: Merck's Januvia Wins New Uses but Risks Outlined Read more: PRESS RELEASE: Merck's Januvia Wins New Uses but Risks Outlined
- EMedTV: Januvia and Weight Loss
- Medical News Today: Lower Symptomatic Hypoglycaemia Risk With Januvia Compared To Glipizide
- Net Doctor: Januvia
- Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T. 2010;35(9):509-13.
- Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin. 2008;24(2):489-96. doi:10.1185/030079908X261069
- Merck Sharp & Dohme Corp. Possible risks and side effects of januvia.
- Merck Sharp & Dohme Corp. Januvia: Dosing and administration. Last reviewed September 2020.
- Pinto LC, Rados DV, Barkan SS, Leitão CB, Gross JL. Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: A meta-analysis with trial sequential analysis. Sci Rep. 2018;8(1):782. doi:10.1038/s41598-017-19055-6
- Xia C, Goud A, D'souza J, et al. DPP4 inhibitors and cardiovascular outcomes: safety on heart failure. Heart Fail Rev. 2017;22(3):299-304. doi:10.1007/s10741-017-9617-4
- Food & Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015.
- Dungan K, DeSantis A. Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus. UptoDate. 2019.
- Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141(1):150-6. doi:10.1053/j.gastro.2011.02.018
- Food and Drug Administration. Medication guide: Januvia (sitagliptin). 2013.
- Food and Drug Administration. FDA approves new treatment for diabetes. Oct. 2006.
Shelley Moore is a journalist and award-winning short-story writer. She specializes in writing about personal development, health, careers and personal finance. Moore has been published in "Family Circle" magazine and the "Milwaukee Sentinel" newspaper, along with numerous other national and regional magazines, daily and weekly newspapers and corporate publications. She has a Bachelor of Science in psychology.